Market Place
Sourcing Support
Oncopeptides Expands WODA Partnership To Africa And Eurasia
04 Sep 2024 //
GLOBENEWSWIRE
Oncopeptides and Vector Pharma Announce Collab to Provide Pepaxti to Patients
27 Mar 2024 //
GLOBENEWSWIRE
FDA formally pulls Oncopeptides` cancer drug after prolonged back-and-forth
23 Feb 2024 //
ENDPTS
CDER challenges Oncopeptides’ appeal over Pepaxto withdrawal
13 Sep 2023 //
ENDPTS
Oncopeptides provides update on Pepaxto US marketing authorization
07 Dec 2022 //
PRNEWSWIRE
Oncopeptides` Pepaxti has been granted marketing authorization in the UK
11 Nov 2022 //
PRNEWSWIRE
Oncopeptides says trial data good, but not enough to sway FDA
28 Oct 2022 //
FIERCEPHARMA
Oncopeptides`s Pepaxti (melphalan flufenamide) Receives Approval in Europe
06 Sep 2022 //
EMA
Oncopeptides phase 3 OCEAN study published in the Lancet Haematology
12 Jan 2022 //
PRNEWSWIRE
Oncopeptides presents new melflufen data at ASH
10 Dec 2021 //
PRNEWSWIRE
Oncopeptides withdraws Pepaxto® in US, scale down organization and focus on R&D
22 Oct 2021 //
PRNEWSWIRE
FDA warns of myeloma drug Pepaxto`s death risk
30 Jul 2021 //
FIERCEPHARMA
Oncopeptides AB: Phase 3 OCEAN study demonstrates that melflufen is at least
25 May 2021 //
PRNEWSWIRE
FDA Approves Oncopeptides´ PEPAXTO® (melphalan flufenamide) for Patients
01 Mar 2021 //
PRNEWSWIRE
Oncopeptides Submits a New Drug Application to the FDA for Accelerated Approval
29 Jun 2020 //
PRNEWSWIRE
Oncopeptides Reinitiates Patient Enrollment to the Melflufen Clinical Program
28 May 2020 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.